TGF-β-Induced TMEPAI Promotes Epithelial–Mesenchymal Transition in Doxorubicin-Treated Triple-Negative Breast Cancer Cells via SMAD3 and PI3K/AKT Pathway Alteration
Bantari W K Wardhani,Melva Louisa,Yukihide Watanabe,Rianto Setiabudy,Mitsuyasu Kato,Bantari WK Wardhani
DOI: https://doi.org/10.2147/BCTT.S325429
2021-09-21
Breast Cancer: Targets and Therapy
Abstract:Bantari WK Wardhani, 1, 2 Melva Louisa, 3 Yukihide Watanabe, 4 Rianto Setiabudy, 3 Mitsuyasu Kato 4 1 Biomedical Sciences, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; 2 Department of Pharmacology, Faculty of Military Pharmacy, Indonesia Defense University, West Java, Indonesia; 3 Department of Pharmacology and Therapeutics, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; 4 Department of Experimental Pathology, Graduate School of Comprehensive Human Sciences, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan Correspondence: Melva Louisa Department of Pharmacology and Therapeutics, Faculty of Medicine Universitas Indonesia, Jl. Salemba Raya No. 6, Jakarta Pusat, Jakarta, 10430, Indonesia Tel +62 21 3193-481 Email Introduction: Epithelial–mesenchymal transition (EMT) and overexpression of drug efflux transporters have been reported to cause doxorubicin resistance. Our previous study indicated that TMEPAI (transmembrane prostate androgen-induced protein) attenuated doxorubicin sensitivity in triple-negative breast cancer cells. However, how TMEPAI contributes to doxorubicin resistance in TNBC remains unclear. Thus, the present study aimed to elucidate the mechanism of TMEPAI in doxorubicin resistance in triple-negative breast cancer cells. Methods: We used BT549, triple-negative cells wild type (WT), and BT549 TMEPAI knock-out. Both cells were treated with TGF-β 2 ng/mL for 24 hours, followed by TGF-β 2 ng/mL and doxorubicin 12.9 nM for another 24 hours. Afterward, the cells were harvested and counted. Cells were further lysed and used for RT-PCR and Western blot analysis. We determined the expression levels of proliferation, apoptosis, EMT markers, and drug efflux transporters. Additionally, we investigated the expressions of PI3K as well as SMAD3 and AKT phosphorylation. Results: TNBC cells were shown to be less sensitive to doxorubicin in the presence of TMEPAI. TMEPAI was shown to alleviate the mRNA expressions of apoptosis markers: Bax, Bcl2, Caspase-3, and Caspase-9. Our results indicated that the presence of TMEPAI greatly amplifies EMT and increases drug efflux transporter expressions after doxorubicin treatment. Furthermore, our findings demonstrated that TMEPAI reduced the action of doxorubicin in inhibiting SMAD3 phosphorylation. TMEPAI was also shown to modify the effect of doxorubicin by reducing PI3K expressions and Akt phosphorylation in triple-negative breast cancer cells. Conclusion: Our findings indicate that TMEPAI promotes EMT and drug efflux transporters at least in part by shifting doxorubicin action from SMAD3 phosphorylation reduction to PI3K/AKT inhibition in triple-negative breast cancer cells. Keywords: PMEPAI, TGF-β, SMAD3, vimentin, E-cadherin, drug efflux transporters Female breast cancer is still a global burden, being the predominant type of cancer and the leading cause of cancer-related mortality and morbidity. 1 Triple-negative breast cancer (TNBC) is one of the types of breast cancer with the lack of molecular marker expressions: estrogen receptor (ER), progesterone receptors, and human epidermal growth factor 2 (HER2) molecular markers. Patients with the TNBC subtype are associated with a more aggressive disease state and poorer prognosis than non-TNBC. 2–4 Currently, the backbone of treatments for TNBC patients is limited to cytotoxic agents such as anthracyclines, alkylators, and taxanes, still with evolving protocols. 2,5–7 Despite the benefit of systemic chemotherapy in improving outcomes of TNBC patients, the problem with chemoresistance is significant, which accounts for about 90% of treatment failure cases. 8–11 Various mechanisms have been suggested to be associated with cancer resistance to chemotherapy. Some of the proposed causes include the ABC transporter-mediated drug efflux, epithelial–mesenchymal transition (EMT), hypoxia, cancer stem cells and the regulation of several networks of signaling pathways. 2,12–14 In TNBC, TGF-β1 was found to play a critical role in treatment-resistant development. In a recent study, Xu et al revealed that endogenous TGF-β1 affects cancer cell stemness and causes an increase in anti-apoptotic markers as well as EMT after low-dose epirubicin treatments. 15 Our previous study showed that TGF-β-induced TMEPAI (transmembrane prostate androgen-induced protein) caused the decrease anticancer response of TNBC to doxorubicin and paclitaxel. 16 Overexpression of TMEPAI was found in many types of cancer, including breast cancer. Singha et al reported that more patients with invasive type have high expressions of TMEPAI compared with t -Abstract Truncated-